Panel V The Future of Wellbeing

This Panel discusses "The Future of Well Being" and "Self Directed Biological Transformation Initiative research study." It will feature Dr. Paul Mills, Dr. Rudolph Tanzi, Dr. Elissa Epel, and Dr. P. Murali Doraiswamy.

Paul Mills (PhD) who is a professor of psychiatry in the behavioral medicine program at UCSD. He is a long-standing National Institutes of Health supported clinical investigator with expertise in cardiovascular and stress physiology as well as psychoneuroimmune processes in wellness disease. His interests include examining the effects of complementary and alternative medicine treatments for fatigue, pain, physical functioning, and PTSD. He has published over 300 manuscripts and book chapters on these topics.

Dr. Rudolph Tanzi is Director of the Genetics and Aging Research Unit at Massachusetts General Hospital and the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School.

Dr. Tanzi co-discovered three of four known Alzheimer's disease genes and directs the Alzheimer's Genome Project, which has identified several other Alzheimer's genes. He also co-discovered the Wilson's disease gene and other neurological disease genes. He is co-founder of several biotech companies , including Prana Biotechnology, which has the promising Alzheimer's drug, PBT2, in clinical trials.

Dr. Elissa Epel (PhD) is an Associate Professor at UCSF in the department of Psychiatry. Dr. Epel received her BA in Psychology from Stanford and PhD in Clinical and Health Psychology from Yale. Her research investigates the intricacies of the mind body connection. In particular, she studies psychological and behavioral processes related to chronic psychological stress that accelerate biological aging, and how mindfulness-bases interventions might slow cellular aging.

Dr. P. Murali Doraiswamy is a Professor of Psychiatry and Medicine at Duke University and a leading physician scientist in the area of mental health, cognitive neuroscience and mind-body medicine. He has co-authored more than 250 scientific reports and conducted landmark clinical trials of both pharmacologic, integrative and lifestyle interventions for neuropsychiatric disorders.